Today we have the pleasure of speaking with Josh Bartch, the CEO of Mydecine, a research & development company with a special interest in psilocybin and psychoactive treatments. We discuss the origins of their work, their team, and current research and practices in the field.

Topics covered:

Mydecine's mission and commitment to human benefit via fungal discovery
Psilocybin treatment for PTSD and other mental health concerns
Machine-learning based drug discovery
Formulation and commercialization of psychedelic therapeutics
The deficiencies in chemical compounds in psilocybe mushrooms
Varietals of psilocybin-containing mushrooms
Collaborative and intern opportunities at Mydecine’s facilities
Describing new compounds in functional mushrooms
Bureaucracy of importing and researching psychedelic mushrooms
Bioavailability of psilocybin

Managing ethical clinical research


Show notes:

Mydecine website: https://www.mydecine.com/
Josh Bartch LinkedIn:   / josh-bartch-a5361b96  
MindLeap app: https://mindleap.health/